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Iki Adachi, MD,* Lyn Edmonds, MCLIP,† and Fujian Song, BMed, MMed, PhD‡
Introduction: A large number of trials have evaluated the efficacy
of postoperative chemotherapy on survival after resection for lung
cancer, and a smaller number have evaluated preoperative chemo-
therapy on survival for potentially resectable lung cancer, but no
direct comparison has yet been published comparing the two ap-
proaches.
Methods: We conducted a systematic review of randomized trials,
extracted time-to-event data using Parmar methods (when not re-
ported), used random effects meta-analysis to evaluate overall and
disease survival treatment effects and performed indirect compari-
son meta-analysis to obtain the relative hazards of postoperative to
preoperative administration on survival.
Results: Data were abstracted from 32 randomized trials involving
more than 10,000 participants, with 22 trials administering postop-
erative and 10 trials administering preoperative chemotherapy. For
overall survival, the hazard ratios were 0.80 (0.74–0.87; p  0.001)
and 0.81 (0.68–0.97; p  0.024) in postoperative chemotherapy
group and preoperative chemotherapy group, respectively. Using
indirect comparison meta-analysis, the relative hazards of postoper-
ative compared with preoperative administration was 0.99 (0.81–
1.21; p  0.91). For disease-free survival, the hazard ratios were
0.76 (0.67–0.86; p  0.001) and 0.79 (0.63 to 1.00; P  0.050) in
postoperative chemotherapy group and preoperative chemotherapy
group, respectively. Using indirect comparison meta-analysis, the
relative hazards of postoperative compared with preoperative ad-
ministration was 0.96 (0.77–1.20; p  0.70).
Conclusions: In patients with resectable lung cancer, there was no
evidence of a difference in overall and disease-free survival between
the timing of administration of chemotherapy (postoperative versus
preoperative).
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In the past two decades, a large number of trials investigatedthe impact of postoperative (adjuvant) chemotherapy on
survival after lung resection for non-small cell lung cancer,
and four ensuing meta-analyses reported pooled hazard ratios
in favor of chemotherapy ranging from 0.74 to 0.87.1–4 A
smaller number of trials have been conducted to evaluate the
impact of preoperative (induction, neoadjuvant) or perioperative
chemotherapy before lung resection, and again, four other meta-
analyses reported pooled hazard ratios in favor of chemother-
apy with hazard ratios ranging from 0.66 to 0.88.5–8 In 2007,
the results of LU22/Nederlandse Vereniging van Artsen voor
Longziekten en Tuberculose/European Organisation for Re-
search and Treatment of Cancer, a multicenter, international,
and the largest preoperative chemotherapy trial to date, were
published,8 and the mid-term results from Southwest Oncol-
ogy Group 9900, a multicenter North American trial, were
announced at the American Society of Clinical Oncology
conference in Chicago,9 both adding considerably to the body
of evidence evaluating the impact of preoperative chemother-
apy on survival in patients with resectable lung cancer.
As no published trial has directly compared the out-
come of preoperative versus postoperative chemotherapy, the
current surge of information leaves physicians and surgeons
alike wondering if there are any differences in survival
regarding the timing for administration. The aim of our study
is to conduct a systematic review of randomized trials to
perform indirect comparison meta-analysis to estimate rela-
tive impact of the timing of the administration of chemother-
apy on survival in patients with operable lung cancer.
METHODS
Search Strategy
We performed a systematic literature search of Medline
(1950 to August 2007), Embase (1996 to August 2007), and
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Cochrane Library 2007, issue 3. To achieve the maximum
sensitivity of the search strategy, we used appropriate free
text and thesaurus terms including “Non-Small Cell Lung
Carcinoma,” “Adjuvant Chemotherapy,” and “Neoadjuvant
Chemotherapy” (full search strategy can be obtained from
Lyn Edmonds on request). We also searched trial registers on
the Internet, abstracts from major thoracic surgery scientific
meetings 2005 to 2007, and reference lists of all relevant
studies. No restrictions were placed on language in any of the
searches. Authors of previous studies were contacted for
further information where required.
Study Selection
All studies evaluating chemotherapy and surgery for
non-small cell lung cancer were included. No restrictions
were placed on abstracts, conference proceedings, or lan-
guage. Our exclusion criteria were studies that were not
randomized, studies that were not confined to general che-
motherapy (e.g., biologic agents or radiotherapy) or did not
have a surgery-only arm and studies in which survival rates
could not be discerned. A given patient population was only
used once: if the same population appeared in other publica-
tions, the article that provided the most complete follow-up
data on survival was selected.
Each individual trial was evaluated on the Downs and
Black quality assessment tool,10 a list of 27 criteria that
evaluates study reporting external and internal validities and
has been ranked among the top 6 quality assessment scales
suitable for use in systematic reviews.11
Data Abstraction
Three investigators (G.H., A.P., E.L.) assessed English
language articles according to the predetermined eligibility
criteria and discordances were resolved by consensus. Japa-
nese and Chinese were assessed by two pairs of investigators
(I.A., E.L.) and (F.J.S., E.L.), respectively. Percentages were
converted into whole numbers for the purpose of reporting
and analyses. Where there was more than one chemotherapy
and surgery subgroups, the results were entered separately as
two trials.12 Results were analyzed by timing of administra-
tion of chemotherapy in postoperative and preoperative
groups. The preoperative group included trials of periopera-
tive administration (chemotherapy given before and after
surgery) as analyzed by all previous meta-analyses on the
subject.5–8
Statistical Methods
Where published, hazard ratios for overall and disease
free survival were extracted directly from the manuscript.
Where hazard ratios were not reported, they were calculated
from published summary statistics or survival plots using the
method of Parmar (F.J.S., E.L.).13
Random effects meta-analysis was performed by com-
bining the results of reported or calculated individual trial
hazard ratios comparing chemotherapy and surgery to surgery
alone. To evaluate the impact of timing of chemotherapy and
survival, indirect comparison meta-analysis14–17 was per-
formed comparing postoperative to preoperative (including
perioperative) administration of chemotherapy as the primary
outcome (postoperative chemotherapy was chosen as the
baseline comparator because it had a larger number of stud-
ies, therefore more statistical weight). The secondary out-
come was disease-free survival. The validity of adjusted
indirect comparison depends on the assumption that trials are
similar in terms of moderators of relative effect, or the results
of one set of trials are generalizable to patients included in
another set of trials.16 An adjusted indirect comparison can be
valid even when the baseline risk of patients was different
between trials, as long as the relative effect (such as relative
risk, odds ratio) was generalizable between trials.
For sensitivity analyses, we repeated the estimates
obtained by indirect comparison meta-analysis using random
effects meta-regression to screen for any important differ-
ences that may have resulted from the inclusion of trials of
perioperative administration of chemotherapy (uncommon in
clinical practice), tegafur/uracil (UFT) administration (not
internationally available), studies with only stage I disease
(this comparison was performed between reported clinical
stage I preoperative chemotherapy studies and pathologic
stage I postoperative chemotherapy studies), studies in which
radiotherapy was administered, the year of the commence-
ment of each trial, and by substitution of the hazard ratios
obtained by studies of individual patients data meta-analyses
where available. Random-effects meta-regression analyses
were conducted using STATA “metareg” command, in which
log hazard ratio was the dependent variable, timing of ther-
apy, and other study-level variables as the independent vari-
ables. The meta-regression analysis was weighted by the
inverse of variance.
Cumulative data meta-analysis was used to evaluate the
impact of the increasing information with time for preoperative
and perioperative chemotherapy studies, and Begg’s test were
used to test for evidence of small study effects, acknowledging
a lack of statistical power in trials with small sample sizes.
Potentially relevant studies 
identified and screened for 
retrieval (n=112) 
Studies that were not 
randomised (n=24), or not 
primary results of a 
randomised trial (n=6), or 
did not use generalised 
chemotherapy (n=9), or did 
not contain a non-
intervention arm (n=15)
Potentially appropriate 
studies to be included in 
the meta-analysis (n=58) 
Studies included in the 
meta-analysis (n=42) 
RCTs with repeat data 
(n=17)
Studies with usable 
information by outcome 
(n=32)
Studies withdrawn because 
primary outcome (survival) 
data not discernable from    
manuscript (n=9) 
FIGURE 1. Quality of reporting of meta-analyses flow dia-
gram.
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Statistical heterogeneity of trial results were tested
using the 2 test of homogeneity and also expressed as I2: the
percentage of total variability attributed to the individual
trials as a measure of inconsistency between studies (a value
of 50% is regarded moderate).18 Statistical analyses were
performed using Stata 9.2 (StataCorp, College Station, TX).
This work was performed without any funding.
RESULTS
Trial Flow, Characteristics, and Quality
Appraisal
Our search strategy identified 112 publications, of
which 58 potentially relevant trials to be included. In total, 17
were excluded for repeat data18–34 and data from 9 studies (1
preoperative and 8 postoperative chemotherapy trials)
could not be extracted for meta-analysis,19–27 leaving 32
trials8,9,12,28–55 that were analyzed: 22 administering post-
operative and 10 administering either perioperative48–50 or
preoperative chemotherapy8,9,51–54 constituting 88% (1637
of 1856) of available patient data. The flow diagram is
illustrated in Figure 1 and the interventions and baseline
characteristics of the included trials are summarized in
Tables 1 and 2, respectively.
Downs and Black assessment was performed for all
manuscripts that have been published, with a higher score
indicating studies of higher reporting quality. The overall
mean (SD) score was 21 (2) of a maximum of 33. The
postoperative and preoperative chemotherapy studies scored
similarly with a mean of 21 (2) and 20 (2), respectively.
Meta-Analysis
For the primary outcome of overall survival using all
available studies (Figure 2), the pooled hazard ratios for death
were 0.80 (0.74–0.87; p  0.001) and 0.81 (0.68–0.97; p 
0.024) in postoperative chemotherapy group and preoperative
TABLE 1. Baseline Stage, Timing, and Type of Chemotherapy
Author
Timing of
Intervention Stage Chemotherapy Regimen(s)
Arriagada et al.29 Postoperative I–III Vindesine cisplatin or vinblastine cisplatin or vinorelbine cisplatin or etoposide cisplatin
Douillard et al.30 Postoperative IB–IIIA Vinorelbine cisplatin
Endo et al.31 Postoperative I–II Tegafur uracil
Feld et al.47 Postoperative I Cyclophosphamide doxorubicin cisplatin
Imaizumi12 Postoperative I Cisplatin vindesine tegafur uracil
Imaizumi12 Postoperative I Tegafur uracil
Kato et al.32 Postoperative I Tegafur uracil
Nakagawa et al.34 Postoperative I Tegafur uracil
Nakagawa et al.33 Postoperative I–III Tegafur uracil or cisplatin vindesine tegafur uracil
Niiranen et al.35 Postoperative I–III Cyclophosphamide doxorubicin cisplatin
Ohta et al.36 Postoperative III Cisplatin vindesine
Park et al.37 Postoperative I Mitomycin C vinblastin cisplatin
Roselli et al.38 Postoperative IB Cisplatin etoposide
Scagliotti et al.39 Postoperative I–IIIA Mitomycin vindesine cisplatin
SGACLC40 Postoperative I–III Cisplatinum adriamycin tegafur uracil
Strauss et al.45 Postoperative IB Paclitaxel carboplatin
Tada et al.28 Postoperative IIIA (N2) Cisplatin vindesine
Ueda et al.41 Postoperative I–IIIA Tegafur uracil
Wada et al.42 Postoperative I–III Cisplatin vindesine tegufar uracil or tegafur uracil
Wada et al.43 Postoperative I–II Cisplatin vindesine mitomycin c tegafur uracil
Waller et al.44 Postoperative I–IV Cisplatin vindesine, mitomycin ifosfamide cisplatin, mitomycin vinblastine cisplatin or
vinorelbine cisplatin
Winton et al.45 Postoperative IB–II Vinorelbine cisplatin
Xu et al.46 Postoperative I–III Cyclophosphamide vincristine adriamycin cisplatin ftorafur
Dautzenberg et al.49 Perioperative I–III Cisplatin vindesine cyclophosphamide
Pass et al.50 Perioperative IIIA Etoposide cisplatinum
Roth et al.48 Perioperative IIIA Cyclophosphamide etoposide cisplatin
Depierre et al.51 Preoperative I–IIIA Mitomycin ifosfamide cisplatin
Gilligan et al.8 Preoperative I–III Mitomycin vinblastine cisplatin or mitomycin ifosfamide cisplatin or paclitaxel carboplatin or
cisplatin gemcitabine or docetaxel carboplatin
Nagai et al.52 Preoperative IIIA Cisplatin vindesine
Rosell et al.53 Preoperative IIIA Mitomycin ifosfamide cisplatin
Pisters9 Preoperative IB–IIIA Paclitaxel carboplatin
Sorensen et al.54 Preoperative IB–IIIA Pacilitaxel carboplatin
Yi et al.56 Preoperative I–III Mitomycin C vindesine cisplatin
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(including perioperative) chemotherapy group, respectively.
There was no evidence of important statistical heterogeneity
between the 2 groups (p  0.81) and overall for all included
trials (232 41.60; p  0.12, I
2  23%). Using indirect
comparison meta-analysis, the relative hazards of postopera-
tive compared with preoperative administration of chemo-
therapy was 0.99 (0.81–1.21; p  0.91).
For the secondary outcome of disease free survival that
could be obtained from 15 postoperative chemotherapy and 7
preoperative chemotherapy trials, the hazard ratios for death
or recurrence were 0.76 (0.68–0.85; p  0.001) and 0.80
(0.66–0.92; p 0.021) in postoperative chemotherapy group
and preoperative (including perioperative) chemotherapy
group, respectively. There was evidence of moderate hetero-
geneity in the postoperative chemotherapy trials (I2  50%,
p  0.014) and mild heterogeneity for preoperative chemother-
apy trials (I2  36%, p  0.154). Using indirect comparison
meta-analysis, the relative hazards of death or recurrence for
postoperative compared with preoperative administration was
0.96 (0.77–1.20; p  0.70).
Sensitivity Analyses
For overall survival using postoperative and purely
preoperative trials, the pooled hazard ratios for death were
0.80 (0.74–0.87; p  0.001) and very similar at 0.81 (0.66–
1.00; p  0.048) in postoperative chemotherapy group and
preoperative (excluding perioperative) chemotherapy group,
respectively, but associated with (borderline) moderate het-
erogeneity (26 11.11; p  0.085; I
2  46%).
On sensitivity analyses by meta-regression, no impor-
tant differences on the indirect comparison of overall survival
between the two regimens were observed after adjustment for
the use of UFT (1.02, 0.87–1.20), stage I patients alone (0.99,
0.83–1.18), radiotherapy (1.03, 0.86–1.24), year of trial com-
TABLE 2. Individual Trial Patient Characteristics and Results
Author Language Size (n)
Postoperative
Radiotherapy Male (%) Age (yr)
Proportion Completed
Chemotherapya
Downs and
Black Score
Arriagada et al.29 English 1867 Yes 80 59, 59b 100 24
Douillard et al.30 English 840 Yes 86 59, 59b 90 24
Endo et al.31 English 221 No 57 64 99 21
Feld et al.47 English 283 No 78 ND ND 16
Imaizumi12 English 150 ND 43 62 100 21
Imaizumi12 English 150 ND 45 62 100 21
Kato et al.32 English 999 No 48 61 100 22
Nakagawa et al.34 English 332 No 61 63 100 21
Nakagawa et al.33 English 267 No 34 60 100 23
Niiranen et al.35 English 110 No 82 57, 59b 87 20
Ohta et al.36 English 181 No 71 58 100 19
Park et al.37 English 118 No 75 58 100 19
Roselli et al.38 English 140 No 84 64 100 21
Scagliotti et al.39 English 1209 Yes 78 61, 61b 90 23
SGACLC40 English 333 No 68 ND 93 21
Strauss et al.45 English 344 ND ND ND ND ND
Tada et al.28 English 119 No 65 62, 62b 100 20
Ueda et al.41 English 30 No 60 61 100 22
Wada et al.42 English 323 No 67 62 50 24
Wada et al.43 English 225 No 68 64 98 19
Waller et al.44 English 381 Yes 69 61, 62b 87 22
Winton et al.45 English 482 No 65 61, 61b 100 22
Xu et al.46 Chinese 70 No 84 55, 56b 100 20
Dautzenberg et al.49 English 26 No 92 56 85 21
Pass et al.50 English 27 Yes 44 53 100 20
Roth et al.48 English 60 Yes 73 ND 89 17
Depierre et al.51 English 355 Yes 89 60, 61b 94 24
Gilligan et al.8 English 519 Yes 72 62, 63b 100 21
Nagai et al.52 English 62 No 66 60 94 19
Rosell et al.53 English 60 Yes 98 62 100 15
Pisters9 English 354 ND ND 65, 65b ND ND
Sorensen et al.54 English 90 ND ND 66, 62b ND ND
Yi et al.56 Chinese 84 No 62 63, 65b 100 ND
a Indicates proportion that have completed at least one cycle.
b Median values given in intervention and control groups, respectively.
ND, not discernable from the manuscript.
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mencement (1.00, 0.84–1.20), when the estimates of individ-
ual patient data meta-analyses were substituted in place of the
included trials (0.97, 0.78–1.20), and when cisplatin only
trials were included (1.05, 0.90–1.22).
Subgroup Analyses
Meta-regression (with all trials included) suggested an
independent, beneficial effect of UFT with a hazard ratio of
0.82 (0.68–0.99; p  0.043). However, it is not possible to
differentiate between a drug and population effect because all
studies that used UFT were Japanese.
Other Outcomes
A cumulative data meta-analysis plot of trials in the
preoperative chemotherapy group demonstrates the large ini-
tial benefit drifting back toward the line of no effect as
increasing data accumulates (Figure 3), explaining the initial
optimistic results reported in earlier meta-analyses.5 This is in
contrast to the more robust estimates of the effects of post-
operative chemotherapy (Figure 4).
For overall survival, there was an evidence of small
study effects when Begg’s test were applied to all trials (p 
0.047). The small study effects largely emanated from the
postoperative chemotherapy (p  0.035) rather than preop-
erative chemotherapy trials (p  0.93). A small study effect
describes the observation where smaller studies tend to report
greater estimates of treatment effect in comparison with
larger studies, potentially as a result from publication bias or
clinical heterogeneity.
DISCUSSION
The results of our systematic review and meta-anal-
yses suggests no important differences in overall or dis-
ease-free survival comparing postoperative with preoper-
ative administration of chemotherapy in patients with
operable lung cancer.
In general, the weight of evidence has supported the use
of adjuvant chemotherapy in patients with operable lung
cancer, but the question of timing of administration was
reviewed in light of the publication of the results of LU22/
Nederlandse Vereniging van Artsen voor Longziekten en
Tuberculose/European Organisation for Research and Treat-
ment of Cancer8 and updated results from Southwest Oncol-
ogy Group 9900 in 2007.9
NOTE: Weights are from random effects analysis
Heterogeneity between groups: p = 0.805
Overall  (I−squared = 23.1%, p = 0.119)
Imaizumi (1), 2005
Xu, 2000
Wada, 1996
Pre−operative
*Roth, 1998
Depierre, 2002
Study ID
Gilligan, 2007
Rosell, 1999
Waller, 2004
Kato, 2004
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Scagliotti, 2003
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FIGURE 2. Forrest plot of overall survival comparing chemotherapy to control.
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No head-to-head evaluation of the impact of timing of
administration on survival has yet been published, although a
number of trials are currently being conducted to evaluate the
timing of administration of chemotherapy on outcomes in
patients undergoing surgery for non-small cell lung cancer.
Among them are trials sponsored by the Chinese Society of
Lung Cancer (NCT00321334), The Samsung Medical Centre
and Eli Lilly (NCT 00329472), and The National Cancer
Center in Korea (NCT 00398385). An ongoing study, the
NATCH trial, has already been criticized (before the study
has been completed) for lacking statistical power to answer
the question definitively with only 200 patients per group.
The critics go on to mention that trials of a similar design are
unlikely to be mounted in the future as “more interesting and
compelling questions remain to be answered.”57 Certainly,
this would support using the existing information from more
than 10,000 participants of 31 trials by indirect comparison
meta-analysis, as a versatile technique11,14,15 to compare with
the differences in the timing of administration using surgery
alone as the common comparator.
All previous meta-analyses on “preoperative” adminis-
tration have included trials48–50 that administered chemother-
apy before and after surgery. Currently, few centers adopt
such an approach, and it could be argued that a more valid
comparison would be to only include trial that administered
either postoperative or preoperative administration alone—
the two approaches in contemporary clinical use. The esti-
mate of effect did not change when perioperative chemother-
apy trials were excluded, but there are important caveats of
increased statistical heterogeneity (I2 increased from 32 to
46%) and uncertainty of the overall effect (p value increased
from 0.024 to 0.048).
To place the uncertainty of the estimate-based current
available data into clinical context, we constructed Table 3 to
illustrate the absolute difference in survival by pathologic
stage58 (based on the sixth revision of the Tumor, Node,
Metastasis classification) that can be expected based on a
hazard ratio of 0.99 with a confidence interval of 0.81 to 1.21.
Although the absolute difference in survival between postoper-
ative and preoperative therapy remained very small, less than
1% across all stages, from stages IA to IIB (the conventional
range for surgery), the upper limit of the confidence interval
represents a range of absolute reduction between 4.5 and 10.4%
and the lower limit of the confidence interval represents a range
of absolute increase between 4.2 and 9.7%. From Table 3, one
can appreciate that the size confidence limits of the two treat-
ment effects largely emanates from uncertainty of the estimates
of the preoperative chemotherapy trials.
At the start of the study, we had a consensus that a
relative difference of 20% would represent a clinically mean-
lnhros
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 *Pass, 1992
 Dautzenberg, 1990
FIGURE 3. Cumulative data meta-analysis of preoperative chemotherapy trials.
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ingful difference, unfortunately the confidence intervals were
exactly around this level (19% to 21%), therefore the
interpretation of whether the results of preoperative admin-
istration are “equivalent” is not yet answered and remains
open to debate. Given that the weight of evidence behind
postoperative chemotherapy trials, the increased statistical
heterogeneity and uncertainty of the treatment benefits of
preoperative chemotherapy when trials of perioperative ad-
ministration were excluded, we believe that the weight of
evidence is (marginally) more in favor for postoperative
chemotherapy in patients with resectable lung cancer at the
outset (Table 4).
We have identified the presence of “small-study effect”
in our analyses for overall survival main emanating from the
lnhros
.329995 .5 1 1.5
 Douillard, 2006
 Roselli, 2006
 Nakagawa, 2006
 Strauss, 2006
 Imaizumi (2), 2005
 Park, 2005
 Winton, 2005
 Nakagawa, 2005
 Imaizumi (1), 2005
 Kato, 2004
 Waller, 2004
 Arriagada, 2004
 Ueda, 2004
 Tada, 2004
 Scagliotti, 2003
 Endo, 2003
 Xu, 2000
 Wada, 1999
 Wada, 1996
 SGACLC, 1995
 Feld, 1993
 Ohta, 1993
 Niiranen, 1992
FIGURE 4. Cumulative data meta-analysis of postoperative chemotherapy trials.
TABLE 3. Estimated 5-yr Survival Probability, Impact on Survival and Limits of the Difference Between Postoperative and
Preoperative Administration
Stage
5-yr
Survival
Reported
Postoperative Chemotherapy Preoperative Chemotherapy
Difference
(Postoperative versus Preoperative)
Expected
Lower
95% CI
Upper
95% CI Expected
Lower
95% CI
Upper
95% CI Expected
Upper
95% CI
Lower
95% CI
IA 73 78.4 76.4 80.3 78.1 73.7 81.8 0.30 4.23 4.51
IB 54 63.2 59.8 66.4 62.7 55.2 69.0 0.51 7.20 7.68
IIA 48 58.5 54.6 62.0 57.9 49.4 64.9 0.58 8.14 8.68
IIB 38 50.5 45.9 54.7 49.8 39.7 58.2 0.69 9.71 10.35
IIIA 25 40.1 34.5 45.3 39.3 27.0 49.4 0.84 11.75 12.52
IIIB 19 35.3 29.3 40.9 34.4 21.2 45.3 0.91 12.68 13.53
IV 21 36.9 31.0 42.3 36.0 23.1 46.7 0.88 12.37 13.19
All numbers are given as a percentage. Bold font indicates the tumour stage for which the data is most applicable.
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postoperative chemotherapy trials, which may be, in part,
accounted for by publication bias. We did not include any
abstracts before 2005, as we considered that all good quality
abstracts published before 2005 would be in print by 2008.
This decision excluded the abstract published by Wu et al.59
in 2002, having reviewed the abstract it would not have been
possible to extract the summary data required for meta-
analysis, and inclusion of Wu et al. would not have influenced
our analyses. As the number of patients that received preop-
erative chemotherapy in the study by Waller et al.44 was small
(3%) and there was no breakdown of results by timing of
chemotherapy administration, we classified this study as one
of postoperative chemotherapy.
Random effects meta-analysis tend to give more weight
to smaller studies as compared with fixed effects meta-
analysis, but the primary outcome was not changed when
estimations using a fixed effects model was used. When we
compared the results of our meta-analyses with that previ-
ously published, we highlight the differences largely emanat-
ing from differences in the selection criteria of included trials,
and the updates published in abstract or full format.
CONCLUSIONS
In patients with resectable lung cancer, there was no
evidence of a difference in overall and disease-free survival
between the timing of administration of chemotherapy (post-
operative versus preoperative).
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